Hyo-Jin Ro

Hyo-Jin Ro

Auto-generated profile, based on publicly available information

Hyo-Jin Ro

Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul 03083, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Cell Reports Physical Science
Verified
Journal Article
Open access
MKMinki Kang
Minki Kang
NJNayoon Jang
Nayoon Jang
YKYoung-Jun Kim
Young-Jun Kim
HRHyo-Jin Ro
Hyo-Jin Ro
DKDabin Kim
Dabin Kim
SKSang-Woo Kim
Sang-Woo Kim
Effective mitigation technology to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is required before achieving population immunity through vaccines. Here we demonstrate a virus-blocking textile (VBT) that repulses SARS-CoV-2 by applying repulsive Coulomb force to respiratory particles, powered by human body triboelectric energy harvesting. We show that SARS-CoV-2 has negative charges, and a human body generates high output current of which peak-to-peak value reaches 259.6 μA at most, based on triboelectric effect. Thereby, the human body can sustainably power a VBT to have negative electrical potential, and the VBT highly blocks SARS-CoV-2 by repulsion. In an acrylic chamber study, we found that the VBT blocks SARS-CoV-2 by 99.95%, and SARS-CoV-2 in the VBT is 13-fold reduced. Our work provides technology that may prevent the spread of virus based on repulsive Coulomb force and triboelectric energy harvesting.

10 June 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
KJKyeongseok Jeon
Kyeongseok Jeon
HRHyo-Jin Ro
Hyo-Jin Ro
JKJoowan Kim
Joowan Kim
YLYebeen Lee
Yebeen Lee
UPUni Park
Uni Park
NCNam-Hyuk Cho
Nam-Hyuk Cho
Severe fever with thrombocytopenia syndrome (SFTS) is a life-threatening tick-borne viral infection characterized by high fever, thrombocytopenia, and severe inflammation, with no effective treatments now available. Through comprehensive analysis of bone marrow and peripheral blood mononuclear cells in mice and from patients with SFTS, we identified interleukin-27 (IL-27) as a key driver of disease progression. Elevated IL-27 levels promoted emergency hematopoiesis and impaired protective B cell development and antibody production, resulting in worsened inflammation and ineffective viral control. Inducing IL-27 expression in monocytes and B cells triggered a vicious inflammatory cycle, exacerbating the severity of SFTS. Neutralizing IL-27 in a lethal mouse model of SFTS improved survival, reduced viral loads, and restored antiviral immunity, highlighting IL-27 as a promising therapeutic target for SFTS.